Fate Therapeutics is a high-risk, high-upside bet on off-the-shelf iPSC cell therapy disrupting autologous CAR T through safer, cheaper, outpatient-ready treatments.
Overview
Fate Therapeutics is a pre-commercial clinical-stage biotech developing first-in-class, off-the-shelf iPSC-derived cellular immunotherapies. Its platform aims to solve the major limitations of autologous CAR T—manufacturing delays, variability, high cost, toxic conditioning, and specialized-center delivery. Lead programs target autoimmune disease and solid tumors, especially FT819 for SLE/lupus nephritis and FT836 for metastatic colorectal cancer. The company has no product revenue and relies mainly on Ono collaboration revenue, but its outpatient-ready, zero-to-low-conditioning approach could materially expand cell therapy adoption if clinical and regulatory milestones succeed.